Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity

Fabian Richter a,b, Kirstin A. Zettlitz a,b*, Oliver Seifert c, Andreas Herrmann c, Peter Scheurich a,b, Klaus Pfizenmaier a,b, and Roland E. Kontermann a,b

*Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany; a Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany; bBaliopharm, Basel, Switzerland

ABSTRACT
Selective inhibition of tumor necrosis factor (TNF) signaling through the proinflammatory axis of TNF receptor 1 (TNFR1) while leaving pro-survival and regeneration-promoting signals via TNFR2 unaffected is a promising strategy to circumvent limitations of complete inhibition of TNF action by the approved anti-TNF drugs. A previously developed humanized antagonistic TNFR1-specific antibody, ATROSAB, showed potent inhibition of TNFR1-mediated cellular responses. Because the parental mouse antibody H398 possesses even stronger inhibitory potential, we scrutinized the specific binding parameters of the two molecules and revealed a faster dissociation of ATROSAB compared to H398. Applying affinity maturation and re-engineering of humanized variable domains, we generated a monovalent Fab derivative (13.7) of ATROSAB that exhibited increased binding to TNFR1 and superior inhibition of TNF-mediated TNFR1 activation, while lacking any agonistic activity even in the presence of cross-linking antibodies. In order to improve its pharmacokinetic properties, several Fab13.7-derived molecules were generated, including a PEGylated Fab, a mouse serum albumin fusion protein, a half-IgG with a dimerization-deficient Fc, and a newly designed Fv1-Fc format, employing the knobs-into-holes technology. Among these derivatives, the Fv13.7-Fc displayed the best combination of improved pharmacokinetic properties and antagonistic activity, thus representing a promising candidate for further clinical development.

Introduction
Tumor necrosis factor (TNF) is a pro-inflammatory cytokine with pleiotropic activity on various cell types and a key factor in initiation and maintenance of chronic inflammatory diseases. Consequently, anti-TNF therapies, including anti-TNF antibodies (infliximab, adalimumab, golimumab, certolizumab pegol) and a soluble TNF receptor 2 (TNFR2) fusion protein (etanercept), have been developed as therapeutic entities and approved for various indications such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis.1,2

TNF is expressed as a transmembrane type 2 protein (tmTNF) capable of binding and activating the two TNF receptors TNFR1 and TNFR2.3–5 TNFα converting enzyme-mediated cleavage converts TNF into a soluble protein (sTNF),6 which can still bind both receptors; however, it is only able to efficiently activate TNFR1.7,8 Importantly, the two TNF receptors exhibit diametrically opposed (dichotomic) activities, with TNFR1 being primarily responsible for pro-inflammatory responses and TNFR2 primarily involved in tissue homeostasis, protection and regeneration.9–12 The approved anti-TNF agents neutralize both tmTNF and sTNF, thus globally blocking TNF activities.13 Various adverse effects are related to this global inhibition, including common and opportunistic infections, reactivation of latent tuberculosis, lupus-like symptoms, demyelination, psoriasis, sarcoidosis, and an increase of malignancies, such as lymphomas.14–16

Selective inhibition of TNFR1 has emerged as novel approach for treatment of TNF-mediated inflammatory diseases.16–19 We previously developed a humanized anti-TNFR1 antibody (ATROSAB) that blocks receptor activation by TNF and lymphotoxin.20,21 ATROSAB, which is an IgG1 antibody deficient in Fcγ receptor and complement binding, demonstrated a protective role in a mouse model of N-methyl-D-aspartate-induced acute neurodegeneration by shifting the anitithetic activity of TNF towards TNFR2.22 Moreover, both H398 and ATROSAB ameliorated disease in a model of multiple sclerosis in TNFR1-humanized mice9,23 and ATROSAB was well tolerated in a preclinical safety study in cynomolgus monkeys (unpublished data). However, because in the absence of TNF ATROSAB showed in a narrow dose range a marginal agonistic activity in vitro, equivalent to about 1–3% of a TNF-induced response,21 we sought to improve antagonistic activity and
safety of this TNFR1-selective antibody by developing monovalent derivatives of ATROSAB. By applying affinity maturation by random and site-directed mutagenesis, as well as developing newly humanized variants based on alternative germline sequences, we developed a Fab (clone 13.7) with improved antagonistic activity. Furthermore, we generated and compared half-life-extended variants thereof applying modification with polyethylene glycol (PEGylation), fusion to serum albumin, an IgG half-antibody format, and a novel heterodimeric Fv-Fc format.

Results

Comparison of bioactivity of ATROSAB and its parental antibody H398

In accordance with previous findings,20 ATROSAB and H398 bound to human TNFR1-Fc in an enzyme-linked immunosorbent assay (ELISA) with similar EC_{50} values of 0.25 nM and 0.15 nM, respectively (Figure 1a). Using quartz crystal microbalance (QCM) measurements, similar apparent affinities of ATROSAB and H398 were determined for binding to immobilized human and rhesus TNFR1-Fc. However, reducing antigen density on the chip to favor monovalent interactions revealed an approximately 3-fold lower apparent affinity of ATROSAB. This was caused mainly by faster dissociation of ATROSAB from the receptor, reflected by a higher k_{off} value of $4.7 \times 10^{-3}$ s^{-1} (Figure 1b) compared to H398, with a k_{off} value of $6.2 \times 10^{-4}$ s^{-1} (Figure 1c, Table 1). Consequently, a slower dissociation of monovalently bound H398 from TNFR1, and hence, a longer receptor occupation, could contribute to a superior blockade of TNFR1.

Affinity maturation and framework exchange of ATROSAB

In order to increase its affinity, and thus its antagonistic activity, the single-chain variable fragment (scFv) of ATROSAB (scFv IZI06.1)20 was subjected to a first affinity maturation approach using site-directed mutagenesis of exposed residues within individual complementarity-determining regions (CDRs) (L1 and H2, CDR1 of the light chain and CDR2 of the heavy chain) or combinations of CDRs (H1/L2 and H2/L1) and selection by phage display against human TNFR1-Fc. For one of the selected clones, scFv IG11, which carries 6 mutations within CDRH2 (EIVPTQGEAKYNDFKKA, mutated residues are underlined), we observed a 3.9-fold slower receptor dissociation (Figure 1c, Table 1) and a 1.6-fold higher bioactivity in terms of inhibition of TNF-induced TNFR1 activation in a HT1080-based interleukin-8 (IL-8) release assay (Figure 2b). This clone was subjected further to a random mutagenesis approach, resulting in

![Figure 1. Receptor binding ATROSAB and H398.](image)

**Table 1.** Comparison of bioactivity of ATROSAB and H398.

|          | ATROSAB* | H398* | fold change |
|----------|----------|-------|-------------|
| EC_{50}, ELISA (nM) | 0.25 | 0.15 | 1.7 |
| k_{on}, high density chip (M^{-1}s^{-1}) | 0.01 | 0.06 | 1.8 |
| k_{off}, high density chip (M^{-1}s^{-1}) | $9.4 \times 10^{-6}$ | $7.5 \times 10^{-5}$ | 1.2 |
| k_{on}, high density chip (s^{-1}) | $1.0 \times 10^{-4}$ | $4.7 \times 10^{-5}$ | 2.1 |
| k_{on}, low density chip (M^{-1}s^{-1}) | 4.5 | 1.6 | 2.8 |
| k_{off}, low density chip (M^{-1}s^{-1}) | $1.0 \times 10^{-6}$ | $3.9 \times 10^{-6}$ | 2.6 |
| k_{off}, low density chip (s^{-1}) | $4.7 \times 10^{-3}$ | $6.2 \times 10^{-4}$ | 7.6 |
| K_{D}, nM | 188 | 51 | 49 |
| IC_{50}, nM | 33 | 20 | 9.8 |

*apparent affinities, determined by measuring bivalent IgG binding to bivalent human TNFR1-Fc.

**Table 2.** Characterization of scFv 13.7 in comparison to intermediate fragments scFv IG11 and scFv T12B and to the parental scFv IZI06.1.

| scFv | IZI06.1 | IG11 | T12B | 13.7 |
|------|---------|------|------|------|
| EC_{50} (nM) | 1.29 | 0.39 | 0.43 | 0.34 |
| k_{on} (M^{-1}s^{-1}) | $9.0 \times 10^{-4}$ | $8.5 \times 10^{-4}$ | $5.3 \times 10^{-4}$ | $2.9 \times 10^{-4}$ |
| k_{off} (s^{-1}) | $1.7 \times 10^{-2}$ | $4.3 \times 10^{-3}$ | $2.6 \times 10^{-3}$ | $1.6 \times 10^{-3}$ |
| K_{D}, nM | 188 | 51 | 49 | 54 |
| IC_{50}, nM | 33 | 20 | 9.8 | 7.1 |

MABS 167
another clone, scFv T12B, exhibiting 2 additional mutations in VH (Q1H, T53S, VH = variable domain of the heavy chain) and one in VL (S91G, VL = variable domain of the light chain). ScFv T12B revealed similar binding capacity compared to scFv IG11 in QCM and an ELISA (Table 2, Fig. S1, Figure 2a). Of note, scFv T12B displayed reduced dissociation from immobilized TNFR1-Fc in QCM experiments revealing a rate constant of $2.6 \times 10^{-3}$ s$^{-1}$ as compared to $k_{off}$ values of $1.7 \times 10^{-2}$ s$^{-1}$ and $4.3 \times 10^{-3}$ s$^{-1}$ for scFv IZ106.1 and scFv IG11, respectively (Fig. S1, Table 2). This translated into a further increased inhibitory activity of scFv T12B for TNF-induced IL-8 release from HT1080 cells by a factor of 3.4, compared to scFv IZ106.1 (Figure 2b, Table 2).

In a further approach, the humanization of H398 was revisited by an exchange of VH and VL framework regions of H398 with alternative germline genes in order to address the possibility of suboptimal CDR arrangement in IZ106.1 after the initial humanization. Humanized versions with alternative framework regions (3–11*01 for VH and 1–39*02 for VL, using two variants for each germline differing in one amino acid position, VH: R or A at position 71, VL: I or V at position 2) were generated and combined with each other and with the VH and VL domains of scFv T12B, which was selected for this approach as the candidate with the most promising binding behavior (Fig. S2). All newly generated scFv molecules were expressed and, in case of sufficient productivity, analyzed for binding to TNFR1-Fc in ELISA, as well as inhibition and TNF-mediated TNFR1 activation in IL-8 release experiments (data not shown). Compared to scFv T12B, the most promising candidate, scFv 13.7 (composed of VH T12B and a newly humanized VL domain), revealed almost identical binding to human TNFR1-Fc in ELISA and QCM (Figure 2a, Fig. S1, Table 2), as well as slightly improved inhibition of TNF-induced IL-8 release from HT1080 cells (Figure 2b). Furthermore, scFv 13.7 possessed an improved thermal stability with a melting temperature ($T_m$) of 65 °C compared to 55 °C for scFv T12B, as determined by dynamic light scattering (Figure 2c–e).

**Binding of IgG 13.7 and Fab 13.7 to human TNFR1**

Based on the newly humanized and affinity-matured version 13.7, an IgG and a Fab with constant regions identical to ATROSAB were generated (IgG 13.7, Fab 13.7) and produced in transiently transfected HEK293T cells. Proteins were purified by affinity chromatography using protein A for IgG 13.7 and Kappa-Select for Fab 13.7. Correct assembly and integrity of IgG 13.7 and Fab 13.7 were confirmed by SDS-PAGE. In analytical size-exclusion chromatography (SEC), IgG 13.7 and Fab 13.7 as well as the reference proteins ATROSAB and its Fab (Fab ATR) revealed one single peak (Figure 3a–c).

Binding of the proteins to human TNFR1-Fc was analyzed by ELISA, revealing EC$_{50}$ values of 0.76 nM for IgG 13.7 and 1.4 nM for Fab 13.7. In comparison to ATROSAB, binding of IgG 13.7 to TNFR1 was improved 1.4-fold, while Fab 13.7 bound to human TNFR1 8.7-fold stronger than Fab ATR (Figure 3d). In addition, the proteins were analyzed by QCM for binding to immobilized human TNFR1-Fc using a moderate receptor density (86 Hz). Fab ATR showed a rapid dissociation from the chip, resulting in a $K_d$ value of 30 nM as analyzed by the “one to one” algorithm (Table 3, Figure 3f). In contrast, Fab 13.7 revealed a reduced dissociation from immobilized TNFR1-
Fc, substantiated by a $K_D$ value of 1.6 nM, i.e., a 25-fold increased affinity (Table 3, Figure 3h). ATROSAB dissociated with biphasic kinetics from the receptor, indicating mono- and bivalent binding events with calculated $k_{off}$ values of $2.2 \times 10^{-2}$ s$^{-1}$ and $4.1 \times 10^{-4}$ s$^{-1}$ and $K_D$ values of 78 nM and 0.38 nM, respectively, in an analysis using a "one to two" binding algorithm (Table 3, Figure 3e). In contrast, IgG 13.7 showed a very slow dissociation from the chip of moderate receptor density, rendering discrimination between mono- and bivalent binding impossible. Thus, based on Fab 13.7, the described approach of affinity maturation and framework replacement resulted in a strongly improved binding to TNFR1.

---

**Figure 3.** Expression, purification and receptor binding of 13.7 derived IgG and Fab. Purity and correct assembly were analyzed by analytical size exclusion chromatography (a, Yarra SEC-2000 column, flow rate 0.5 ml/min) and SDS-PAGE (b, 12% separation gel, reducing conditions; c, 8% separation gel, non-reducing conditions). The indicated molecular weights were interpolated using a standard curve of proteins with known mass and retention time. Binding to human TNFR1 was evaluated in ELISA (d, n = 3, mean ± SD) and QCM experiments (e-h). In QCM measurements, concentrations between 64 nM and 4 nM (ATROSAB and IgG13.7) or 128 nM to 8 nM (FabATR and Fab13.7), were analyzed in triplicates. Measurements (grey, dotted line) and fit (black, solid) are shown.
Selectivity and cross-reactivity of Fab and IgG 13.7 for TNFR1

Selectivity of Fab 13.7 and IgG 13.7 for binding to TNFR1 was confirmed by ELISA with immobilized TNFR1-Fc and TNFR2-Fc fusion proteins (Fig. S3a). Furthermore, species cross-reactivity of Fab 13.7 was analyzed using TNFR1 from different species (Fig. S3b). Fab 13.7 bound to human and rhesus TNFR1-Fc, while no binding could be detected for the mouse and rat TNFR1-Fc. ATROSAB showed a similar binding pattern. The mouse TNFR1-specific control antibody H55R-170 bound to mouse TNFR1-Fc as well as to rat TNFR1-Fc fusion proteins (Fig. S3c), confirming the integrity of the coated mouse and rat TNFR1-Fc fusion proteins.

In vitro bioactivity of IgG 13.7 and Fab 13.7

In a first set of in vitro experiments, we analyzed potential agonistic activities of IgG 13.7 and Fab 13.7. The monovalent Fabs (Fab ATR and Fab 13.7) did not show any signs of receptor activation as determined by the release of IL-8 (Figure 4a) from HT1080 cells, compared with the cellular background (Table 4).

In addition, no induction of TNFR1-mediated cytotoxicity in Kym-1 cells was detected for both proteins (Figure 4b, Table 4). In accordance with previous experiments, ATROSAB showed a marginal potential to activate TNFR1 in IL-8 release experiments using HT1080 cells (Figure 4a). The detected IL-8 level at the peak concentration was 1.8-fold higher in comparison to the IL-8 release from unstimulated cells, corresponding to around 1% of the value obtained for TNF at a concentration of 33 nM (peak response in titration assay, data not shown) (Table 4). In cell death induction experiments using Kym-1 cells, however, no receptor activation could be detected (Figure 4b, Table 4). Surprisingly, IgG 13.7 strongly activated TNFR1, resulting in released IL-8 amounts of ~ 87% compared to TNF (33 nM, Figure 4a, Table 4). In a Kym-1 cytotoxicity assay, IgG 13.7 induced cell death in up to 100% of the cells as determined by crystal violet staining (Figure 4b, Table 4). Consequently, only Fab 13.7 was employed to further test the inhibitory potential on TNF-induced cytokine release from HT1080 cells (Figure 4c) and apoptosis of Kym-1 cells (Figure 4d). In these assays, TNF was used at a concentration of 0.1 nM to induce activation of TNFR1 in IL-8 release assays using HT1080 cells and at a concentration of 0.01 nM in Kym-1 cell death induction experiments. Interestingly, monovalent Fab ATR revealed similar activities as bivalent ATROSAB in IL-8 release experiments with IC_{50} values of 151 nM and 118 nM (Figure 4c). Furthermore, similar IC_{50} values of 37 nM and 24 nM were observed in the cytotoxicity assay using Kym-1 cells (Figure 4d). Of note, Fab 13.7 revealed superior inhibitory potential towards TNFR1 compared to Fab ATR, but also to the bivalent IgG ATROSAB, resulting in an IC_{50} value of 19 nM using HT1080 cells (Figure 4c). An IC_{50} value of 4.7 nM was determined in the cell death induction assay using Kym-1 cells (Figure 4d, Table 4). Taken together, these data demonstrate an improved inhibitory potential of Fab 13.7 compared to ATROSAB and Fab ATR, and a lack of agonistic activity.

Table 3. Affinity determination of IgG13.7 and Fab13.7.

|                  | ATROSAB | IgG 13.7 | Fab ATR | Fab 13.7 |
|------------------|---------|----------|---------|----------|
| Bmax1 (Hz)       | 16.8    | 6.4      | 8.9     |          |
| Bmax2 (Hz)       | 10.7    | 32.7     | -       | -        |
| k_{on1} (M^{-1}s^{-1}) | 2.6 x 10^6 | 5.0 x 10^5 | 4.7 x 10^5 |          |
| k_{off1} (s^{-1}) | 2.2 x 10^{-2} | 1.5 x 10^{-2} | 7.3 x 10^{-3} |          |
| IC_50 (nM)       | 78      | -        | 30      | 1.6      |
| k_{on2} (M^{-1}s^{-1}) | 1.1 x 10^6 | 6.6 x 10^5 | -       | -        |
| k_{off2} (s^{-1}) | 4.1 x 10^{-4} | 5.4 x 10^{-4} | -       | -        |
| K_D2 (nM)        | 0.38    | 0.68     | -       | -        |

*apparent affinities, determined by measuring bivalent IgG binding to bivalent human TNFR1-Fc; 1: monovalent interaction; 2: bivalent interaction.

Figure 4. Bioactivity of 13.7 antibodies.

The potential of IgG13.7 and Fab13.7 to stimulate TNFR1 on the surface of HT1080 and Kym-1 cells was analyzed by detection of IL-8 (a) release as well as by the induction of cell death (b). The inhibitory activity of Fab13.7 in the respective assays was analyzed (c and d) with respect to receptor stimulation by 0.1 nM TNF (c) or 0.01 nM TNF (d). ATROSAB and FabATR served as controls. Stimulatory experiments were performed twice (a and b, n = 2, mean ±SD), inhibitory experiments were performed three times (c and d, n = 3, mean ±SD).
In order to rule out a potential agonistic activity in the presence of cross-linking anti-drug antibodies, IL-8 release assays were performed in the presence of an anti-human IgG serum preparation produced in goat and specific for the Fab. Binding of the goat-anti-human IgG serum to immobilized Fab 13.7 was demonstrated by ELISA revealing half-maximal binding at around 1 nM (Figure 5). Incubation of increasing concentrations of Fab 13.7 with cross-linking goat anti-human Fab serum did not promote any TNFR1-mediated induction of IL-8 release (Figure 5). In contrast, the anti-Fab serum induced increased levels of IL-8 in a concentration-dependent manner in the presence of ATROSAB (Figure 5).

## Antibody-dependent cross-linking of anti-TNFR1 antibodies

In order to rule out a potential agonistic activity in the presence of cross-linking anti-drug antibodies, IL-8 release assays were performed in the presence of an anti-human IgG serum preparation produced in goat and specific for the Fab. Binding of the goat-anti-human IgG serum to immobilized Fab 13.7 was demonstrated by ELISA revealing half-maximal binding at around 1 nM (Figure 5). Incubation of increasing concentrations of Fab 13.7 with cross-linking goat anti-human Fab serum did not promote any TNFR1-mediated induction of IL-8 release (Figure 5). In contrast, the anti-Fab serum induced increased levels of IL-8 in a concentration-dependent manner in the presence of ATROSAB (Figure 5).

## Plasma half-life of Fab 13.7

Aiming at therapeutic application, plasma half-life is a critical factor to be considered in order to maintain a prolonged drug exposure. The pharmacokinetic (PK) properties of Fab 13.7, which possesses a molecular mass of approximately 47 kDa, was analyzed in transgenic C57BL/6J mice expressing the extracellular domain of human TNFR1 instead of the respective mouse protein (TNFR1kie mice). After a single intravenous (i. v.) injection of Fab 13.7, an initial half-life of 0.08 h, a terminal half-life of 1.4 h, and an area under the curve (AUC) of 4.2 µg/ml × h was determined. These values were similar to those of Fab ATR (t_{1/2,initial} 0.17 h, t_{1/2,terminal} 2.2 h, AUC 6.7 µg/ml × h) (Figure 6). Thus, as expected, both proteins are more quickly cleared from circulation compared to ATROSAB, which exhibits an initial half-life of 0.44 h, a terminal half-life of 32.1 hours and an AUC of 181 µg/ml × h, respectively.

### Table 4. Bioactivity of ATROSAB and 13.7 antibodies.

|                 | TNF (33 nM) | ATROSAB | Fab ATR | IgG 13.7 | Fab 13.7 | Cells* |
|-----------------|-------------|----------|---------|----------|----------|--------|
| IL-8 release (pg/ml) | 20,850 | 240 | 128 | 4231 | 138 | 137 |
| IC_{50, IL-8} (nM) | - | 118 | 151 | - | 19 | - |
| Cytotoxicity (%) | 92 | - | - | up to 100 | - | - |
| IC_{50, Cytotox} (nM) | - | 24 | 37 | - | 4.7 | - |

*unstimulated cells

![Figure 5](image_url). Fab13.7 lacks agonistic activity upon crosslinking. Binding of a goat anti-human Fab antibody to Fab 13.7 in ELISA (a) and (b) the effect of this goat anti-human Fab antibody (64 µg/ml) on the stimulatory activity of Fab13.7 towards TNFR1 was analyzed in an IL-8 release assay using HT1080 cells and compared to ATROSAB (n = 2, mean ±SD).

![Figure 6](image_url). Pharmacokinetic study on Fab13.7 and half-life engineered variants. PK profiles were obtained after i.v. bolus injection of 25 µg protein using C57BL/6J mice (n = 3) homozygously bearing the extracellular domain of human TNFR1 at the locus of the mouse gene. Initial and terminal half-lifes as well as the area under the curve were calculated after detection of remaining active protein in serum samples by ELISA.
**Half-life extended monovalent 13.7 derivatives**

In order to extend the half-life of antibody 13.7, we generated several monovalent derivatives exhibiting an increased molecular mass and/or utilizing neonatal Fc receptor (FcRn) recycling. In a first approach, a Fab’ fragment (Fab’ 13.7) was generated by introducing a free cysteine residue at the C-terminus of the first constant domain of the heavy chain (CH1), which was chemically coupled to a branched PEG_{2kDa} moiety, resulting in Fab 13.7PEG (Fig S4). Furthermore, Fab 13.7 was fused through its Fd and a short flexible linker to the N-terminus of mouse serum albumin (MSA) (Fab13.7-MSA) (Fig. S5). A monovalent Fab-Fc fusion protein was generated by fusing Fab 13.7 to a modified Fc, lacking the cysteines in the hinge region as well as the ability to dimerize via the CH3 domain, resulting in a one-armed half-IgG molecule (IgG_{half}13.7) (Fig S6). Finally, a monovalent Fv-Fc molecule was generated by fusing the VH and VL domains to a heterodimerizing knob-into-hole (kih) Fc chain, lacking the cysteines in the hinge region (Fv13.7-Fc_{chih}, Fig S7).

These molecules were produced in HEK293-6E suspension cells after transient transfection and purified by affinity chromatography and subsequent preparative SEC in the cases of Fab13.7-MSA, IgG_{half}13.7 and Fv13.7-Fc_{chih} (SEC profiles and pooled fractions are displayed in Fig. S8). Molecular integrity was confirmed by SDS-PAGE analysis (Fig. S4c-S7c) and analytical SEC (Fig. S4d-S7d). Binding of all 13.7 derivatives to human TNFR1-Fc was demonstrated in ELISA. Here, compared to Fab 13.7, a slightly reduced binding was observed for Fab13.7PEG, Fab13.7-MSA and IgG_{half}13.7, while binding of Fv13.7-Fc_{chih} was not affected (Table 5, Fig. S4e-S7e). None of the newly generated Fab 13.7 derivatives showed detectable agonistic activity towards TNFR1 in an IL-8 release assay using HT1080 (Fig. S4f-S7f). Furthermore, inhibition of IL-8 release from HT1080 cells, induced by 0.1 nM TNF, was slightly reduced by factors ranging from 1.5 to 3.3 compared to Fab 13.7. Fv13.7-Fc_{chih} showed the lowest change in bioactivity (Table 5, Fig. S4g-S7g).

PK properties of the newly generated Fab 13.7-derived molecules were determined in TNFR1KO mice after an i.v. injection of 25 μg protein. IgG_{half}13.7 exhibited a similar terminal half-life of 1.5 hours as Fab 13.7 (1.4 h, Table 5, Figure 6). The AUC value of IgG_{half}13.7 was increased by a factor of 7.1 compared to Fab 13.7 (Table 5, Figure 6). In contrast, Fab13.7PEG, Fab13.7-MSA, and Fv13.7-Fc_{chih} revealed strongly extended terminal half-lives with values of 14.4 h, 9.7 hours and 10.5 h, respectively, and strongly increased AUC values (Table 5, Figure 6).

**Discussion**

In this study, we identified a difference in TNFR1 interaction between two closely related TNFR1-specific antibodies, mAb H398 and its humanized derivative ATROSAB, the latter displaying a faster dissociation upon monovalent interaction with human TNFR1 (Figure 1, Table 1). To improve this parameter, the scFv IZI06.1, composed of the VH and VL of ATROSAB, was subjected to affinity maturation by phage display. After two consecutive rounds of site-directed and random mutagenesis, isolated clones revealed stronger binding to TNFR1 (scFv IG11; Figure 2a; Fig S1; Table 2) and improved inhibition of TNFR1 activation (scFv T12B, Figure 2a, b; Fig S1; Table 2), respectively. The lead candidate was further combined with newly humanized variable domains based on VH and VL germline genes with the most human-like amino acid composition. Functional scFvs were obtained in the combination of a newly humanized VL domain and the VH domain of the affinity matured scFv T12B, constituting the new scFv 13.7, which revealed similar binding to TNFR1-Fc and similar inhibition of TNF-induced activation of TNFR1 compared to its parental scFv T12B (Table 2, Fig. S1 and S2). However, scFv 13.7 showed higher thermal stability compared to scFv T12B and other newly humanized candidates, indicating an overall improved molecular structure, which was demonstrated to result in a higher product quality as revealed by a recent study showing a connection between thermal stability of antibodies, solubility and long-term stability (Fig. 2).

Compared to the initially humanized scFv IZI06.1, the combined engineering resulted in an ~3.5-fold higher apparent monovalent affinity than scFv IZI06.1 as determined by QCM (Fig. S1, Table 2). However, QCM measurements might be affected by the presence of multimers, resulting in varying K_D values as observed for scFv IZI06.1 when compared to previously published data. Consequently, Fab 13.7 was produced, lacking aggregates and multimers, which revealed an 18.8-fold improved monovalent affinity when compared to Fab ATR (Figure 3, Table 3), comprising VH and VL of scFvIZI06.1.

Most importantly, the monovalent Fab 13.7 exhibited increased neutralizing activity compared to ATROSAB while lacking any agonistic activity, and thus represents a valuable alternative to the bivalent ATROSAB exhibiting marginally stimulatory activity (Figure 4, Table 4). Surprisingly, IgG

---

**Table 5. Bioactivity of half-life engineered Fab13.7 Variants.**

| Molecule       | MW [kDa] | S_0 [nm] | ELISA Binding EC_{50} [nM] | IL-8 Inhibition IC_{50} [nM] | Initial Half-Life [h] | Terminal Half-Life [h] | Area Under The Curve [μg/ml*h] |
|----------------|----------|----------|-----------------------------|-------------------------------|----------------------|-----------------------|-------------------------------|
| Fab13.7PEG     | ~88      | n.d.     | 1.3                         | 55.9                          | 6.8 ± 1.14           | 14.4 ± 7.2             | 346.0 ± 20.52                |
| Fab13.7-MSA    | 114      | 5.0      | 0.7                         | 65.5                          | 1.20 ± 1.51          | 9.7 ± 3.0              | 193.4 ± 65.1                 |
| IgG_{half}13.7 | 73       | 4.1      | 0.8                         | 63.3                          | 0.10 ± 0.11          | 1.5 ± 0.2              | 29.7 ± 9.4                   |
| Fv13.7-Fc_{chih} | 76      | 3.8      | 0.3                         | 30.7                          | 0.54 ± 0.25          | 10.5 ± 2.2             | 109.0 ± 22.2                 |
| Fab 13.7      | 47       | 2.6      | 0.4                         | 20.0                          | 0.08 ± 0.06          | 1.4 ± 0.9              | 4.2 ± 0.4                    |
| ATROSAB       | 146      | 4.9      | 0.2                         | 97.8                          | 0.44 ± 0.19          | 32.1 ± 11.1            | 180.7 ± 29.8                 |
13.7 exhibited pronounced agonistic capacity when tested in vitro in different assays (Figure 4, Table 4). Taking into account that members of the TNFR superfamily (TNFRSF) typically require oligomeric receptor cluster formation, mediated by receptor-ligand/receptor-antibody binding and receptor-receptor interactions, this agonistic activity might be attributed to the improvement in affinity, especially to slower dissociation from TNFR1, which resulted in formation of stable signaling competent receptor-antibody complexes. These complexes must be formed also in the case of ATROSAB, but they seemed to be less stable, as indicated by its only marginal activation of TNFR1 on the cell surface, which might be due to the rather transient interaction between ATROSAB and TNFR1.

The agonistic power of IgG13.7 could also be the result of other effects. First, changes within the antibody’s paratope might have slightly altered the epitope or induced an epitope drift-like phenomenon. Such mechanisms have been described for in vivo matured antibodies, resulting in different binding behavior that fosters the formation of larger receptor clusters on the cell surface. Second, the changes within the CDRs have enabled additional interactions between TNFR1 and the engineered antibody IgG 13.7, which could be involved in some kind of induced-fit mechanism as described for antibodies against protein or hapten antigens, leading to structural changes in the antigen, which have been described to possibly contribute to the activation of TNFR1. Third, the changes during the process of maturation and exchange of framework regions could have altered the angle between TNFR1 and the Fab part of IgG13.7, rendering it more likely for the second Fab arm of the antibody to bind to another TNFR1 molecule, supporting the engagement of IgG 13.7 in larger receptor clusters that promote sustained receptor activation. The latter argument would imply that ATROSAB, despite its two binding sites, represents a functionally monovalent molecule under most conditions. This reasoning is supported by the observation that ATROSAB shows no or only marginal receptor activation on its own and requires sustained secondary antibody-mediated receptor cross-linking to be converted into an antagonist. Moreover, ATROSAB and its corresponding Fab revealed identical bioactivities with respect to the inhibition of TNF-mediated activation of TNFR1, further supporting the view that bivalent binding of ATROSAB to cell surface TNFR1 is a rare event.

The fact that the monovalent interaction of 13.7 at the site of TNF binding resulted in sustained inhibition of TNFR1 activation underlines the potential of Fab 13.7 as a drug candidate amenable for further development. Aside from a clear improvement of bioactivity of Fab 13.7 (~ 5-fold compared to ATROSAB), the absence of any agonistic potential even in the presence of secondary crosslinking antibodies appears as a major advantage (Figure 5). Indeed, anti-drug antibodies (ADAs) are known to represent a major hurdle in the application of protein therapeutics. For example, in a previously published study, two of five patients treated with 2 to 10 μg/kg of an anti-human TNFR1 VH domain antibody showed mild to moderate signs of cytokine release syndrome. This effect was attributed to pre-existing auto-antibodies directed against the VH, which were detected in 50% of the patients in a retrospective study. In the case of the anti-TNF drugs infliximab and adalimumab, a study revealed the development of ADAs in 50% and 31% of the patients, respectively, resulting in the termination of the applied therapy. Of course, the apparent lack of conversion of the TNFR1 agonist 13.7 into an agonist by secondary crosslinking antibodies, as suggested from the data obtained so far, requires additional studies to confirm this feature.

The short plasma half-life of the Fab 13.7 is a potential draw back for further drug development. Therefore, we generated several half-life extended derivatives of Fab 13.7, including PEGylated Fab, fusion of the Fab to MSA or a dimerization-impaired IgG Fc part (half-IgG), as well as an Fv-Fc fusion protein utilizing a knobs-into-holes Fc (Fig. S4-S7, Table 5). All newly designed molecules revealed improved PK properties (Figure 6, Table 5), but all molecules also showed somewhat reduced binding to TNFR1-Fc and inhibitory potential of TNF-induced responses in vitro (Fig. S4-S7, Table 5). This reduction in binding affinity after molecular modification is a well-described phenomenon, especially in the case of PEGylated Fabs, as demonstrated for Fabs directed against diverse targets. While Fab13.7PEG demonstrated superior PK behavior, which corresponded well with previously published PK data of an Alexa-Fluor-labeled anti-TNF Fab (certolizumab PEGol) in mice, it also showed the strongest impairment of function. The molecule Fv13.7-Fc<sub>kih</sub>, which was engineered for heterodimeric assembly of two peptide chains by use of the knobs-into-holes technology, revealed a strongly improved PK profile, compared to the parental Fab, and showed the lowest impact on binding and antagonistic activity compared to all other generated Fab 13.7 derivatives.

Taken together, the novel monovalent TNFR1 inhibitor Fab 13.7 was generated by affinity maturation and framework exchange, resulting in stronger inhibition of TNF-induced cellular responses. The Fab was converted into the fusion protein Fv13.7-Fc<sub>kih</sub>, improving its PK properties. The characteristics of the newly generated monovalent Fv13.7-Fc<sub>kih</sub> are suitable to fulfill the previously proposed advantages of selective TNFR1 antagonism over systemic TNF blockade in TNFR1-mediated diseases due to unaffected TNFR2 signaling and broader range of action due to simultaneous TNF and lymphotoxin α (LTA) inhibition. The latter is of special interest regarding the demonstrated pro-inflammatory role of LTA in different mouse models, e.g., collagen-induced arthritis and experimental autoimmune encephalomyelitis (EAE). LTA was furthermore reported to be elevated in the synovium as well as in the serum of rheumatoid arthritis (RA) patients. Of note, RA patients with resistance to infliximab treatment responded to etanercept, a TNFR1-Fc fusion protein that also neutralizes LTA. Finally, Fv13.7-Fc<sub>kih</sub> might also hold potential for the application in oncologic indications, as suggested by recent reports on the involvement of TNFR1 in tumor-associated lymphangiogenesis or Helicobacter pylori infection-mediated development of gastric cancer in mouse models. Thus, Fv13.7-Fc<sub>kih</sub> represents...
a lead candidate for a drug development and for preclinical and clinical evaluation in diseases with a recognized pathogenic role of TNF and/or LT.

Materials and methods

Materials

ATROSAB and human TNFR1-Fc were provided by Baliopharm (Basel, Switzerland). H398 (HM2020SP-b) was purchased from Hycult biotech (Plymouth Meeting, PA, USA). Anti-His-HRP ( HIS-6 His-Prob-HRP, sc-8036) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-human Fab (Goat, polyclonal, 2085–01) from SouthernBiotech, (Birmingham, AL, USA), anti-human IgG (Fab specific, A 0293) and anti-human IgG (Fc specific, A 0170) from Sigma-Aldrich (Taufkirchen, Germany) and anti-M13 monoclonal HRP-Conjugate (27,942,101) was purchased from GE Healthcare (Chalfont St Giles, GB).

Antibody production

All variants of ATROSAB and 13.7 were cloned into the expression vector pEE14.4 (IgG, Fab) or pSecTagAL1 (Invitrogen) (Fab’, Fv-Fckih, IgGhalsFab-MSA) and produced in stably or transiently transfected HEK293T cells using Lipofection (Lipofectamine™) and in E. coli (library 1), vector pEE14.4 (IgG, Fab) or pSecTagAL1™ (IgG, Fc) and produced in E. coli (library 2) and using an Äkta purifier with a Superdex 200 10/300 GL column at a flow rate of 0.5 ml/min using phosphate-buffered saline (PBS) as liquid phase. ScFv were produced in E. coli and purified from periplasmic extracts by IMAC (Ni-NTA Agarose, 64–17-5, Macherey-Nagel, Düren, Germany).

Generation of phage libraries

Individual CDR libraries were generated by amplification of the parental scFv gene, using PCR technology with degenerated primers containing randomized codons (NNK) at selected positions within the CDRs (library 1, 6 residues [H: 31, 32, 33; L: 50, 53, 56]; library 2, 12 residues [H: 50, 52, 53, 54, 56, 58, 61; L: 27D, 27E, 28, 30, 32]; library 2a, 7 residues [H: 50, 52, 53, 54, 56, 58, 61]; library 2b, 5 residues [L: 27D, 27E, 28, 30, 32]). Briefly, after digesting with Nhel and BamHI (library 1), Xmal and Pstl (library 2) or Ncol and Pstl, the PCR products were ligated overnight at 16 °C into phagemid vector pHENIS, containing the parental scFv with a frameshift mutation and a stop codon in order to avoid wild-type phage in the libraries. DNA was precipitated and transformed by electroporation into E. coli TG1. Library EP03 was generated by error-prone PCR using the GeneMorph II Random Mutagenesis Kit (200,550, Agilent Technologies, Santa Clara, CA, USA) according to the manufacturers protocol. Standard sequencing primers were used to amplify plasmid pHENIS-scFvLib2a_huBR6_IG11 while the conditions were adjusted to introduce a moderate number of mutations by using 0.1 µg template DNA in a 30-cycles PCR reaction. After digest with Ncol and NotI, the PCR product was ligated into phagemid vector pHENIS overnight at 16 °C. DNA was precipitated and transformed by electroporation into E. coli TG1.

Phage display

Phage display selections were performed in immunotubes essentially as described. The concentrations of human TNFR1-Fc for coating of immunotubes were decreased from 1 and 0.1 µg/ml in round 1 to 0.1 and 0.01 µg/ml in the last round, respectively. Prior to the first round, a negative selection round was performed using immune tubes with immobilized human TNFR2-Fc (2 µg/ml). In some selections, soluble human TNFR1-Fc (5 µg/ml) was added to the tubes in order to capture quickly dissociating phages and hinder their re-binding to immobilized antigen. Additionally, an off-rate screening step was included in order to evaluate the reduced dissociation from the receptor by QCM technology. The supernatants of rescued monoclonal phages were diluted 1:2 in PBST (PBS, 0.1% Tween 20) and tested on a sensor chip with immobilized human TNFR1-Fc (48 Hz). For reasons of comparison, the running buffer was also mixed 1 to 1 with 2xTY media. The mean value of three measurements was analyzed using the Attaché office software (Attana, Stockholm, Sweden).

Pegylation of Fab13.7

Fab’13.7 was reduced by the addition of tris(2-carboxyethyl) phosphine (TCEP) to a final concentration of 5 mM and incubation for 2 hours at room temperature (RT). Remaining TCEP was removed in a dialysis step against nitrogen-saturated Nellis buffer (10 mM Na2HPO4/NaH2PO4 buffer, 0.2 mM EDTA, 30 mM NaCl, pH 6.7) overnight at 4 °C using a D-Tube™ Dialyzer Mini (MW cut-off 6 – 8 kDa). The reduced Fab’13.7 was mixed with methoxy-PEG-Mal-40K (mPEG-Mal, NEKTAR 2D3Y01) at a molar ratio of 1:10, overlaid with nitrogen in order to avoid re-oxidation and incubated at RT for 1 hour. Finally, free and reactive maleimide groups were quenched by adding L-cysteine (final conc. 100 µM) for 10 minutes at RT. In a final step, PEGylated Fabs were purified using a HiTrap KappaSelect resin as described above.

Protein characterization

Proteins were analyzed by SDS-PAGE and stained with Coomassie-Brilliant Blue G-250. Purity and correct protein characterization was performed using IMAC (Ni-NTA Agarose, 64–17-5, Macherey-Nagel, Düren, Germany) or a HiTrap KappaSelect resin (17–5458-12, GE Healthcare, Chalfont St Giles, GB) followed by gel filtration if necessary (Fab13.7-MSA, IgG hal13.7 and Fv13.7-Fc13b, using an Äkta purifier with a Superdex 200 10/300 GL column at a flow rate of 0.5 ml/min using phosphate-buffered saline (PBS) as liquid phase. ScFv were produced in E. coli and purified from periplasmic extracts by IMAC (Ni-NTA Agarose, 64–17-5, Macherey-Nagel, Düren, Germany).
Alcohol dehydrogenase (150 kDa), BSA (66 kDa), carbonic anhydrase (29 kDa), FLAG peptide (1 kDa).

**Thermal stability**

Protein aggregation was analyzed by dynamic light scattering using the ZetaSizer Nano ZS (Malvern, Herrenberg, Germany) increasing temperature stepwise from 35 °C to 80 °C with 1 °C intervals and 2 minutes equilibration prior to each measurement. About 100 µg of protein in 1 ml PBS was analyzed and the melting point ($T_m$) retrieved upon visual analysis of the increasing signal (kcps).

**Enzyme-linked immunosorbent assay**

The indicated proteins were immobilized in 96-well microtiter plates at a concentration of 1 µg/ml in PBS overnight at 4 °C. Residual binding sites were blocked using 2% skim milk in PBS (MPBS, 200 µl/well) for 2 hours at RT. Samples were diluted in MPBS, applied to the plates and incubated for another hour at RT. For detection purposes, HRP-labeled or biotin-labeled detection antibodies were applied to the plate for another hour at RT. In the case of biotin-labeled detection antibodies, the plates were subsequently incubated at RT for 1 hour with an HRP-conjugated streptavidin reagent (Immunotools, IL kit component). Bound protein species were detected with 1 mg/ml TMB solution, 0.006% H$_2$O$_2$ in 100 mM Na-acetate buffer, pH 6 at RT, reaction was terminated using 50 µl 1 M H$_2$SO$_4$ and absorption was measured at a wavelength of 450 nm. The plates were washed three times with PBST (PBS + 0.005% Tween20) and twice with PBS in between each incubation step and in advance of the detection.

**Quartz crystal microbalance**

Binding kinetics were determined by quartz crystal microbalance measurements using a A-100 C-Fast or Cell-200 C-Fast (Attana, Stockholm, Sweden). Human TNFR1-Fc was immobilized on the sensor chip according to the manufacturer’s amine coupling protocol at the indicated densities. Studies were performed using PBST (0.1% Tween-20, pH 7.4) as running buffer at 37 °C, applying a flow rate of 25 µl/min. Reference measurements were performed after every second protein injection using PBST and subtracted from the obtained binding curves. Sensor chips were regenerated after each measurement and reference injection using 25 µl 5 mM NaOH or 20 mM glycine, pH 2.0. Data analysis was performed using Attaché Office Evaluation software (Attana, Stockholm, Sweden) and TraceDrawe (ridgview instruments, Vange, Sweden).

**Interleukin release assay**

HT1080 (IL-8) cells were seeded ($2 \times 10^4$ cells/well) in a 96-well plate and incubated overnight. After exchange of the supernatant in order to remove constitutively secreted interleukin, the cells were incubated with the samples in RPMI 1640 + 5% fetal calf serum (FCS) at 37 °C, 5% CO$_2$. For inhibition experiments, antibody samples and stimulating agent (TNF) were mixed prior to application to the cells. Unstimulated cells or cells treated with TNF alone served as controls. After 16–20 hours, plates were centrifuged at 500 × g for 5 minutes and diluted supernatants were analyzed by ELISA according to the manufacturers protocol (IL-8, 31,670,089, ImmunoTools, Friesoythe, Germany).

**Cytotoxicity assay**

Kym-1 cells ($1 \times 10^4$ per well) were seeded into 96-well microtiter plates and incubated overnight at 37 °C and 5% CO$_2$. Protein dilutions in 5% RPMI 1640 + 10% FCS were applied to the cells and incubated for another 24 hours at 37 °C and 5% CO$_2$. In case of competition assays, both protein species were mixed together prior to application to the cells. The next day, supernatants were discarded and 50 µl/well crystal violet solution (0.5% crystal violet, 20% methanol in H$_2$O) was added to the plates and incubated for 20 minutes at RT. Subsequently, plates were washed in H$_2$O 20 times and air-dried. Remaining crystal violet dye was dissolved by the addition of 100 µl/well methanol. After 10 minutes shaking at RT, the absorbance at a wavelength of 595 nm was determined.

**Pharmacokinetics**

Animal care and experiments were in accordance with federal guidelines and have been approved by university and state authorities. In order to determine PK properties, 12 µg or 25 µg protein were injected i.v. into transgenic C57BL/6J mice bearing the gene of the extracellular domain of human TNFR-1 at the locus of the particular mouse gene (C57BL/6-huTNFRSF1Aecdtm1UEG/izi)). Blood samples were collected from the tail vein after 3 min, 30 min, 1 h, 3 hours and 6 hours as well as after 3 days and 7 days and incubated on ice immediately. After centrifugation (13,000 × g, 4 °C, 10 minutes), serum was separated and stored at 20 °C until analysis. Remaining functional protein in the serum samples was analyzed by ELISA against immobilized human TNFR1-Fc. Data were calculated as percentage of the 3 minutes value.

**Abbreviations**

ATROSAB antagonistic TNF receptor one specific antibody  
AUC area under the curve  
Fab antigen-binding fragment  
Fc crystallizable fragment  
Fv variable fragment  
PEG polyethylene glycol  
QCM quartz crystal microbalance  
TNF tumor necrosis factor  
TNFRI TNF-receptor 1

**Acknowledgments**

We would like to thank Nadine Heidel and Doris Göttsch for excellent technical assistance.
Disclosure statement
FR, KAZ, AH, PS, KP, and REK are named inventors on patents and patent applications covering the 13.7 technology.

Funding
This work was supported by a research grant from Bialiopharm, Basel, CH.

ORCID
Fabian Richter http://orcid.org/0000-0002-9655-4723
Kirstin A. Zettlitz http://orcid.org/0000-0003-4870-6603
Oliver Seifert http://orcid.org/0000-0001-1876-4212
Andreas Herrmann http://orcid.org/0000-0002-4487-2076
Klaus Pfizenmaier http://orcid.org/0000-0002-3441-9227
Roland E. Kontermann http://orcid.org/0000-0001-7139-1350

References
1. Kotsovils S, Andreakos E. Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol. 2014;1060:37–59. PMID:24037835. doi:10.1007/978-1-62703-586-3_6.
2. Fischer R, Kontermann RE, Maier O. Targeting sTNF/TNFRII signaling as a new therapeutic strategy. Antibodies. 2015;4:48–70. doi:10.3390/antib4010048.
3. Brockhaus M, Schoenfeld HJ, Schlæger EJ, Hunziker W, Lesslauer H, Leslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1999;96:3127–3131. PMID:2158104. doi:10.1073/pnas.87.8.3127.
4. Loetscher H, Pan YC, Lahm HW, Gertz R, Brockhaus M, Tabuchi H, Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1999b;61:351–359. PMID:215886. doi:10.1002/8784-90815-10.
5. Loetscher H, Schlæger EJ, Lahm HW, Pan YC, Lesslauer W, Brockhaus M. Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells. J Biol Chem. 1999a;274:20131–20136. PMID:2173696.
6. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner MJ, Stocking KL, Reddy P, Srinivasan S, et al. A metalloproteinase disintegrin that releases tumour-necrosis-factor alpha from cells. Nature. 1997;385:729–733. PMID:9304190. doi:10.1038/385729a0.
7. Grell M, Douni E, Wajant H, Löhnd J, Claus M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793–802. PMID:8521496. doi:10.1016/0092-8674(95)90192-2.
8. Wajant H, Pfizenmaier K, Scheurlen C. Tumor necrosis factor signaling. Cell Death Diff. 2003;10:45–65. PMID:12655295. doi:10.1038/sj.cdd.4401189.
9. Williams SK, Maier O, Fischer R, Fairless R, Hochmeister S, Stojic A, Pick L, Haar D, Musiol S, Storch MK, et al. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS One. 2014;9:e90117. PMID:24587237. doi:10.1371/journal.pone.0072156.
10. Kontermann RE, Münkel S, Neumeyer J, Müller D, Branschädel CJI.0b013e31816a88f9.
11. Williams SK, Fairless R, Maier O, Liermann PC, Fischer R, Eisel OLM, Kontermann RE, Herrmann A, Weksler B, Romero IA, et al. Anti-TNFRII targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018;8:13628. doi:10.1038/s41598-018-31957-7.
12. Van Hauwermeiren F, Vanderbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFRI. Cytokine Growth Factor Rev. 2011;22:311–319. PMID:21962830. doi:10.1016/j.cytogfr.2011.09.004.
13. Kontermann RE, Scheurich P, Pfizenmaier K. Antagonists of TNF action - clinical experience and new developments. Expert Opin Drug Discov. 2009;4:279–292. PMID:23489126. doi:10.1517/174640920785167.
14. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor receptors: clinical utility in autoimmune diseases. Transl Res. 2015;165:270–282. doi:10.1016/j.trsl.2014.09.006.
15. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 2015;165:270–282. doi:10.1016/j.trsl.2014.09.006.
16. Vant Hauwmeirens F, Vanderbroucke RE, Liberty C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFRI. Cytokine Growth Factor Rev. 2011;22:311–319. PMID:21962830. doi:10.1016/j.cytogfr.2011.09.004.
17. Kontermann RE, Scheurich P, Pfizenmaier K. Antagonists of TNF action - clinical experience and new developments. Expert Opin Drug Discov. 2009;4:279–292. PMID:23489126. doi:10.1517/174640920785167.
18. Van Hauwmeirens F, Vanderbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFRI. Cytokine Growth Factor Rev. 2011;22:311–319. PMID:21962830. doi:10.1016/j.cytogfr.2011.09.004.
19. Pfizenmaier K, Kontermann RE, Scheurich P, Pfizenmaier K. Antagonists of TNF action - clinical experience and new developments. Expert Opin Drug Discov. 2009;4:279–292. PMID:23489126. doi:10.1517/174640920785167.
30. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351–2354. PMID:10875917. doi:10.1126/science.288.5475.2351.

31. Branschädel M, Aird A, Zappe A, Tietz C, Krippner-Heidenreich A, Scheurich P. Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness. Cell Signal. 2010;22:404–414. PMID:19879354. doi:10.1016/j.cellsig.2009.10.011.

32. Chan FK. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine. 2007;37:101–107. PMID:17449269. doi:10.1016/j.cyto.2007.03.005.

33. Bock K, Karlsson KA, Strömberg N, Teneberg S. Interaction of viruses, bacteria and bacterial toxins with host cell surface glyco-lipids. Aspects on receptor identification and dissection of binding epitopes. Adv Exp Med Biol. 1988;228:153–186. PMID:2459928.

34. Root-Bernstein R. Rethinking molecular mimicry in rheumatic heart disease and autoimmune myocarditis: laminin, collagen IV, CAR, and BIAR as initial targets of disease. Front Pediatr. 2014;2:285. PMID:25191648. doi:10.3389/fped.2014.00085.

35. Rini JM, Schulze-Gahmen U, Wilson IA. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science. 1992;255:959–965. PMID:15464293. doi:10.1126/science.15464293.

36. Wang W, Ye W, Yu Q, Jiang C, Zhang J, Luo R, Chen HF. Conformational selection and induced fit in specific antibody and antigen recognition: SPE7 as a case study. J Phys Chem B. 2013;117:4912–4923. PMID:23548180. doi:10.1021/jp3010967.

37. Lewis AK, Valley CC, Sachs JN. TNFR1 signaling is associated with backbone conformational changes of receptor dimers consistent with overactivation in the R92Q TRAPS mutant. Biochemistry. 2012;51:6545–6555. PMID:22799488. doi:10.1021/bi300662r.

38. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2006;50:184–195. PMID:10891884. doi:10.1002/mrr.534.

39. Lundkvist Ryner M, Farrell RA, Fogdell-Hahn A. The case for measuring anti-drug antibodies in people with multiple sclerosis. Expert Rev Clin Immunol. 2014;10:697–699. PMID:24780058. doi:10.1586/1744666X.2014.914852.

40. Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33:1192–1203. PMID:23832582. doi:10.1007/s10875-013-9915-0.

41. Mok CC, van der Kleij D, Woblink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–1435. PMID:23887439. doi:10.1007/s10067-013-2336-x.

42. Brocchini S, Godwin A, Balan S, Choi JW, Zloh M, Shaunak S. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev. 2008;60:3–12. PMID:17920720. doi:10.1016/j.addr.2007.06.014.

43. Khalili H, Godwin A, Choi JW, Lever R, Brocchini S. Comparative binding of disulfide-bridged PEG-Fabs. Bioconjug Chem. 2012;23:2262–2277. PMID:22994419. doi:10.1021/bc300372r.

44. Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348:36–41. PMID:19567252. doi:10.1016/j.jim.2009.06.009.

45. Martin PL, Bugelski PJ. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol. 2012;166:806–822. PMID:22168335. doi:10.1111/j.1476-5381.2011.01812.x.

46. Powell MB, Mitchell D, Lederman J, Buckmeier J, Zambill SS, Graham M, Ruddle NH, Steinman L. Lymphotixin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol. 1990;2:539–544. PMID:1707660. doi:10.1093/intimm/2.6.539.

47. Suen WE, Bergman CM, Hjelmström P, Ruddle NH. A critical role for lymphotixin in experimental allergic encephalomyelitis. J Exp Med. 1997;186:1233–1240. PMID:9334362. doi:10.1084/jem.186.8.1233.

48. Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Retino CJ, et al. Targeted depletion of lymphotixin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009;15:766–773. PMID:19561618. doi:10.1038/nm.1984.

49. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheuma-toid arthritis. Eur Cytokine Netw. 1998;9:145–154. PMID:9681390.

50. O'Rourke KP, O'Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, Molloy M, Shanahan F, O’Gara F. High levels of Lymphotixin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int. 2008;28:979–986. PMID:18379788. doi:10.1007/s00296-008-0574-z.

51. Bhushan MK, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotixin alpha? Ann Rheum Dis. 2004;63:1344–1346. PMID:15033655. doi:10.1136/ard.2003.014878.

52. Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, Lim S, Nakamura M, Andersson P, Wang J, Sun Y, et al. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun. 2014;5:4944. PMID:25229256. doi:10.1038/ncomms5944.

53. Oshima H, Ishikawa T, Yoshida GJ, Naoi K, Maeda Y, Naka K, Ju X, Yama Y, Minamoto T, Mukaida N, et al. TNF-α/TNFRI signalling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells. Oncogene. 2014;33:3820–3829. PMID:23975421. doi:10.1038/onc.2013.356.

54. Lou J, Marks JD. Affinity maturation by chain shuffling and site directed mutagenesis. In: Kontermann RE, Dübel S, editors. Antibody engineering. Berlin: Springer; 2010. p. 199. doi:10.1007/978-3-662-04605-0_9.

55. Thie H. Affinity maturation by random mutagenesis and phage display. In: Kontermann RE, Dübel S, editors. Antibody engineering. Berlin: Springer; 2010. p. 199. doi:10.1007/978-3-662-04605-0_9.

56. Kontermann RE. Immunotube selections. In: Kontermann RE, Dübel S, editors. Antibody engineering. Berlin: Springer; 2010. p. 199. doi:10.1007/978-3-662-04605-0_9.